Skip to content

pBFS-guided distinct rTMS targets in treatment of major depressive disorder

Distinct rTMS targets in treatment of major depressive disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069378
Enrollment
Unknown
Registered
2023-03-15
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Active:rTMS

Sponsors

Southeast Hospital Affiliated to Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. DSM-5 diagnosis of depressive disorder, single or recurrent episodes; 2. A total score of at least 20 on the HAMD-17 and Montgomery-Asberg Depression Rating Scale; 3. Aged 18-65 years, female or male; 4. Inadequate response to at least one antidepressant trial of adequate doses and duration; 5. The MSM (Maudsley Staging Method) score = 7; 6. Stable antidepressant regimen for at least 4 weeks before treatment; 7. Educated for at least 5 years; 8. Understand the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. A lifetime psychiatric history of psychotic disorders, bipolar I or II disorders, obsessive-compulsive disorder, secondary depression, etc; 2. Implanted electronic devices (e.g. pacemakers, cochlear implants) or other metallic implants; or contraindications to MRI or contraindications to rTMS treatment; 3. History of seizure disorder (at least 2 unprovoked seizures separated by more than 24 hours, or diagnosis of epilepsy syndrome, or seizures within the past 12 months); 4. Prior treatment with electroconvulsive therapy (ECT), rTMS, or light therapy within 3 months; 5. Systemic brain disease (e.g. ischemic stroke, brain tumor) or traumatic brain injury); 6. Severe heart, liver, kidney disease, diabetes, and other serious physical diseases, etc.; 7. Women who were pregnant, breastfeeding, and intend or may become pregnant during the trial; 8. Drug and alcohol abuse within the past year; 9. First-degree relative with bipolar disorder; 10. Serious suicidal ideation/behavior (e.g. item 10 of MADRS >= 5 points); 11. Difficult to communicate or understand or follow instructions, and be unable to cooperate with the treatment and assessment; 12. Currently participant in clinical trials of other drugs or physical therapy (e.g deep brain stimulation, ECT, rTMS); 13. Investigators think that was inappropriate to participate.

Design outcomes

Primary

MeasureTime frame
Montgomery-Asberg Depression Rating Scale, MADRS;

Secondary

MeasureTime frame
Hamilton Depression Scale, HAMD;Hamilton Anxiety Scale, HAMA;Quick Inventory of Depressive Symptomatology Self-Report, QIDs;Clinical Global Impression-severity, CGI-S;Global Assessment Function, GAF;Side Effect Frequency, intensity, and Burden rating Scale (FIBSER);

Countries

China

Contacts

Public ContactOuyang Lin

Southeast Hospital Affiliated to Xiamen University

15880556766@163.com+86 158 8055 6766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026